Clinical Trial Update: Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] [Phase 3]

View source ↗

Summary

Clinical trial SIENDO (NCT03555422) evaluates maintenance selinexor vs placebo following combination chemotherapy in endometrial cancer; the Phase 3 study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Endometrial Cancer | Phase 3 | Status: COMPLETED